RxDoctor Payments Data

Morris Naus, MD

Gastroenterology · Delray Beach, FLNPI 1598751679

Payments from drug & device makers

$193,162in general payments, 2019–2025

Across 1,035 payments — averaging $186.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$119K
  • Celltrion USA Inc.$23K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$22K
  • Takeda Pharmaceuticals U.S.A., Inc.$10K
  • AbbVie$6K
  • Otsuka America Pharmaceutical, Inc.$4K
  • plus $10K from 40 others

What the payments were for

  • Consulting fees$3,7732%
  • Speaking & faculty fees$135,08270%
  • Travel & lodging$30,09616%
  • Food & beverage$23,75712%
  • Education$4560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$193,162 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$524,536
Medicare patients
931
Services billed
14,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin33$109,174
VoqueznaVonoprazan Fumarate104$77,066
LinzessLinaclotide50$42,804
Dexlansoprazole DrDexlansoprazole48$13,873
ClenpiqSod Picosulf/Mag Ox/Citric Ac61$10,404
Pantoprazole Sodium495$9,220
SutabSod Sulf/Pot Chloride/Mag Sulf38$6,163
Esomeprazole Magnesium160$5,807
Omeprazole270$4,534
Ursodiol15$3,712
Colestipol Hcl33$2,887
Lubiprostone17$1,652
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag13$1,601
Budesonide DrBudesonide13$1,505
Dicyclomine Hcl53$1,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$21,849$109,17433 claims
Phathom Pharmaceuticals, Inc.Voquezna$119,266$77,066104 claims
AbbVieLinzess$5,598$42,80450 claims
Ferring Pharmaceuticals Inc.Clenpiq$343$10,40461 claims
Braintree Laboratories, Inc.Sutab, Suflave$299$7,76451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →